Search

Search Constraints

You searched for: Author/Creator Kircik, L.

Search Results

3. Quality of life and patient‐perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed‐dose combination Cal/BD foam: A post‐hoc analysis of PSO‐LONG. (21st October 2021)

5. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. (1st March 2021)

6. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). (1st March 2021)

7. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). (30th December 2020)